spartalizumab + gemcitabine + cisplatin

**Spartalizumab + gemcitabine + cisplatin** is a combination regimen consisting of spartalizumab, an experimental anti-PD-1 humanized monoclonal antibody, together with gemcitabine and cisplatin, two cytotoxic chemotherapy agents. Spartalizumab blocks the PD-1 immune checkpoint, thereby reactivating T-cell antitumor responses. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while cisplatin is a platinum-based compound that induces DNA crosslinking and apoptosis. This combination is under investigation for use in advanced solid tumors, particularly non-small cell lung cancer (NSCLC), and is designed to leverage complementary mechanisms—immune checkpoint inhibition and cytotoxicity—with potential for synergistic antitumor effects[1].

Other names

spartalizumabgemcitabinecisplatin